Additionally, because PD-L1 immunohistochemical expression was not routinely measured in patients with stage III NSCLC at our center before December 2022, analyses of PD-L1 expression and efficacy were not applicable. This evidence concerns the gene CD274 and non-small cell lung carcinoma.